KNSA Stock Forecast & Price Target

Kiniksa Pharmaceuticals is benefiting from exceptional Arcalyst momentum, with Q3 revenue of $286 million, FY26 guidance raised to $1.045-$1.050 billion, and penetration of the ~14,000 multiple-recurrence RP population still only 23%, leaving substantial runway. The company also appears operationally strong, as operating income reached $54.2 million, net income was $47.3 million, collaboration profit rose 67% year over year to $211.6 million, and cash and investments totaled $568.8 million while positive annual cash flow is still expected. Its outlook is further strengthened by a de-risked pipeline, including KPL-387’s favorable once-monthly profile, expected Ph 3 data in 2H27, and a potential launch in 2028/29, all supported by strong physician and patient preference for broader IL-1 adoption.

Kiniksa Pharmaceuticals is viewed negatively because its valuation depends heavily on Arcalyst’s adoption in recurrent pericarditis, and poorer-than-expected commercial uptake would directly weaken revenue growth and operating leverage. The outlook is further pressured by the risk that better-than-expected competitor products could erode market share and limit the company’s ability to establish a durable franchise in its lead indication. In addition, if biologics for rare diseases cannot secure premium pricing at commercialization, the company’s economics could deteriorate materially, especially given its reliance on the United States for maximum revenue.